Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind placebo-controlled study of efinopegdutide in adults with precirrhotic nonalcoholic steatohepatitis
MOH_2023-06-07_012722Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- May 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of efinopegdutide in metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD) (5 arms), sponsored by Merck & Co. Started May 2023; status: active, not recruiting.
02
Drugs
efinopegdutide
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on MOH_2023-06-07_012722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-06-07_012722.